» Articles » PMID: 35859295

Protective Effect of Astragalus Membranaceus and Astragaloside IV in Sepsis-induced Acute Kidney Injury

Overview
Specialty Geriatrics
Date 2022 Jul 21
PMID 35859295
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute kidney injury (AKI) is the most common target organ damage in sepsis. Sepsis-associated AKI (SA-AKI) may be characterized by damage to the renal tubular epithelium. In this study, the pharmacological mechanisms of Astragalus membranaceus and its active monomer Astragaloside IV (AS-IV) were predicted based on a network pharmacology approach and validated both and using the SA-AKI model.

Method: We constructed an sepsis model using a mouse cecum ligation puncture (CLP) and HK-2 cells were treated with lipopolysaccharide (LPS) to mimic Gram (-) induced sepsis to assess the renal-protective efficacy of Astragalus membranaceus and AS-IV.

Results: The findings demonstrated that Astragalus membranaceus and AS-IV attenuate renal tubular injury in mice with polymicrobial sepsis, including vacuolization, loss of brush border, mitochondrial ultrastructural changes, and increased staining of kidney injury molecule-1 (KIM-1). AS-IV protected human proximal tubular epithelial (HK-2) cells against LPS induced cell viability loss. Both Astragalus membranaceus and AS-IV activated the PI3K/AKT pathway both and , as shown by Western blot and immunohistochemistry analysis.

Conclusion: The findings demonstrate that Astragalus membranaceus and AS-IV protect against sepsis-induced kidney tubular injury by activating the PI3K/AKT pathway.

Citing Articles

Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury.

Chen L, Deng Y, Hu J, Gong X Front Pharmacol. 2025; 16:1539886.

PMID: 40046749 PMC: 11880292. DOI: 10.3389/fphar.2025.1539886.


Therapeutic potential of -based Eefooton in patients with chronic kidney disease: from clinical to bench study.

Lu K, Kuo K, Wu S, Lin C, Lin C, Hou Y Int J Med Sci. 2025; 22(1):227-239.

PMID: 39744164 PMC: 11659832. DOI: 10.7150/ijms.102280.


Role of HSP90 in Type 2 Diabetes Mellitus and Its Association with Liver Diseases.

Nithyasree V, Magdalene P, Praveen Kumar P, Preethi J, Gromiha M Mol Biotechnol. 2024; .

PMID: 39162909 DOI: 10.1007/s12033-024-01251-1.


Metabolomics combined with network pharmacology reveals a role for astragaloside IV in inhibiting enterovirus 71 replication via PI3K-AKT signaling.

Hao J, Zhang X, Hu R, Lu X, Wang H, Li Y J Transl Med. 2024; 22(1):555.

PMID: 38858642 PMC: 11163744. DOI: 10.1186/s12967-024-05355-9.


Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.

Wang X, Luan J, Guo Z Chin J Integr Med. 2024; .

PMID: 38850482 DOI: 10.1007/s11655-024-3805-6.


References
1.
Cheng S, Zhang X, Feng Q, Chen J, Shen L, Yu P . Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway. Life Sci. 2019; 227:82-93. DOI: 10.1016/j.lfs.2019.04.040. View

2.
Zhang R, Zhu X, Bai H, Ning K . Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. Front Pharmacol. 2019; 10:123. PMC: 6393382. DOI: 10.3389/fphar.2019.00123. View

3.
Hopkins A . Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682-90. DOI: 10.1038/nchembio.118. View

4.
Zhang J, Wu C, Gao L, Du G, Qin X . Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv Pharmacol. 2020; 87:89-112. DOI: 10.1016/bs.apha.2019.08.002. View

5.
Shkondrov A, Krasteva I, Bucar F, Kunert O, Kondeva-Burdina M, Ionkova I . A new tetracyclic saponin from L. and its neuroprotective and hMAO-B inhibiting activity. Nat Prod Res. 2018; 34(4):511-517. DOI: 10.1080/14786419.2018.1491040. View